{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:09:23Z","timestamp":1790874563213,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtha.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T21:39:37Z","timestamp":1712871577000},"page":"1880-1893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A"],"prefix":"10.1016","volume":"22","author":[{"given":"Bella","family":"Madan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Raheja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Symington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris V.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Leavitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Reding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"von Drygalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Chambost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chieh","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Osmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony","family":"Dashiell-Aje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.jtha.2024.04.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/PPA.S202773","article-title":"Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom","volume":"13","author":"Carroll","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2024.04.001_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/hae.13377","article-title":"Impact of pain and functional impairment in US adults with haemophilia: patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study","volume":"24","author":"Kempton","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib4","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/hae.12545","article-title":"Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population","volume":"21","author":"Nugent","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O'Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2024.04.001_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.04.001_bib7","first-page":"S3","article-title":"Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia","volume":"90","author":"Witkop","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.04.001_bib8","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.001_bib9","first-page":"1687","article-title":"Patient and parent preferences for characteristics of prophylactic treatment in hemophilia","volume":"9","author":"Furlan","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2024.04.001_bib10","first-page":"5959","article-title":"Real-world rates of bleeding, factor VIII use, and quality of life in individuals with severe haemophilia A receiving prophylaxis in a prospective, noninterventional study","volume":"10","author":"Kenet","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14304","article-title":"Patients' and parents' satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study","volume":"27","author":"Park","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40271-019-00395-6","article-title":"Patient perspectives on novel treatments in haemophilia: a qualitative study","volume":"13","author":"van Balen","year":"2020","journal-title":"Patient"},{"key":"10.1016\/j.jtha.2024.04.001_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.04.001_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib18","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib23","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1111\/hae.14635","article-title":"Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A","volume":"28","author":"Huang","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2022.03.008","article-title":"Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A","volume":"213","author":"Huang","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.04.001_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/hae.12592","article-title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A","volume":"21","author":"Kepa","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2022008948","article-title":"Valoctocogene roxaparvovec gene transfer in participants with HIV","volume":"7","author":"Ragni","year":"2023","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.04.001_bib27","first-page":"S32","article-title":"Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1 [abstract]","volume":"43","author":"Quon","year":"2023","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.04.001_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/PROM.S357555","article-title":"Psychometric validation of the Haemo-QOL-A in participants with hemophilia A treated with gene therapy","volume":"13","author":"Quinn","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.jtha.2024.04.001_bib29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1365-2516.2008.01812.x","article-title":"Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia","volume":"14","author":"Rentz","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/968081","article-title":"Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients","volume":"2014","author":"Varaklioti","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jtha.2024.04.001_bib31","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jtha.2024.04.001_bib32","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2024.04.001_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2516.2006.01186.x","article-title":"Measuring patients\u2019 perceptions on their functional abilities: validation of the Haemophilia Activities List","volume":"12","author":"van Genderen","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jval.2014.07.003","article-title":"Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE)","volume":"17","author":"Recht","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2024.04.001_bib35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jtha.2024.04.001_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib37","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jtha.2023.08.032","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1","volume":"21","author":"O\u2019Mahony","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.001_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.14278","article-title":"Evidence of a disability paradox in patient-reported outcomes in haemophilia","volume":"27","author":"O'Hara","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.001_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MEG.0000000000000233","article-title":"A\u00a0systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes","volume":"27","author":"Radcke","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2024.04.001_bib40","first-page":"709","article-title":"Mildly elevated liver transaminase levels: causes and evaluation","volume":"96","author":"Oh","year":"2017","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jtha.2024.04.001_bib41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib42","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.001_bib43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jtha.2024.04.001_bib44","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2024.04.001_bib45","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.001_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2024.04.001_bib47","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.04.001_bib48","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T01:09:29Z","timestamp":1719623369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1538783624001843"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.04.001","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}